Reply to "Inferring clinical relevance of der p 23 from the restricted effect on treatment outcomes after tablet allergy immunotherapy"

Allergy. 2021 Apr;76(4):1300-1301. doi: 10.1111/all.14636.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Hypersensitivity*
  • Immunoglobulin E
  • Sublingual Immunotherapy*
  • Tablets
  • Treatment Outcome

Substances

  • Tablets
  • Immunoglobulin E